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Recently, multiple breast cancer susceptibility loci have been iden-
tified by several genome-wide association studies (GWAS) or 
studies of specific candidate single-nucleotide polymorphisms 
(SNPs) (1–10). Genetic variants that showed strong statistically 
significant associations with breast cancer risk (odds ratios [ORs] = 
1.15–1.45, P < 5 × 1027) were identified in fibroblast growth factor 
receptor 2 (FGFR2). The vicinity is referred to all genes, not only 
FGFR2. In other words, some of the SNPs mentioned in this para-
graph are located directly within the mentioned genes, some 
others are near the genes. TOX high mobility group box family 
member 3 (TOX3; also known as TNRC9), mitogen-activated 
protein kinase kinase kinase 1 (MAP3K1), caspase 8 (CASP8), 
lymphocyte-specific protein 1 (LSP1), collagen type I alpha 1 
(COL1A1), cytochrome c oxidase assembly homolog 11 (COX11), 
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 Background Recently, several genome-wide association studies have identified various genetic susceptibility loci for breast 
cancer. Relatively little is known about the possible interactions between these loci and the established risk 
factors for breast cancer.
 Methods To assess interactions between single-nucleotide polymorphisms (SNPs) and established risk factors, we pro-
spectively collected DNA samples and questionnaire data from 8576 breast cancer case subjects and 
11 892 control subjects nested within the National Cancer Institute’s Breast and Prostate Cancer Cohort 
Consortium (BPC3). We genotyped 17 germline SNPs (FGFR2-rs2981582, FGFR2-rs3750817, TNRC9-rs3803662, 
2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, CASP8-rs1045485, LSP1-rs3817198, COL1A1-rs2075555, 
COX11-rs6504950, RNF146-rs2180341, 6q25-rs2046210, SLC4A7-rs4973768, NOTCH2-rs11249433, 5p12-rs4415084, 
5p12-rs10941679, RAD51L1-rs999737), and odds ratios were estimated by logistic regression to confirm previ-
ously reported associations with breast cancer risk. We performed likelihood ratio test to assess interactions 
between 17 SNPs and nine established risk factors (age at menarche, parity, age at menopause, use of hormone 
replacement therapy, family history, height, body mass index, smoking status, and alcohol consumption), and 
a correction for multiple testing of 153 tests (adjusted P value threshold = .05/153 = 3 × 1024) was done. Case–
case comparisons were performed for possible differential associations of polymorphisms by subgroups of 
tumor stage, estrogen and progesterone receptor status, and age at diagnosis. All statistical tests were two-sided.
 Results We confirmed the association of 14 SNPs with breast cancer risk (Ptrend = 2.57 × 1023 –3.96 × 10219). Three SNPs 
(LSP1-rs3817198, COL1A1-rs2075555, and RNF146-rs2180341) did not show association with breast cancer risk. 
After accounting for multiple testing, no statistically significant interactions were detected between the 17 SNPs 
and the nine risk factors. We also confirmed that SNPs in FGFR2 and TNRC9 were associated with greater 
risk of estrogen receptor–positive than estrogen receptor–negative breast cancer (Pheterogeneity = .0016 for 
FGFR2-rs2981582 and Pheterogeneity = .0053 for TNRC9-rs3803662). SNP 5p12-rs10941679 was statistically signifi-
cantly associated with greater risk of progesterone receptor–positive than progesterone receptor–negative breast 
cancer (Pheterogeneity = .0028).
 Conclusion This study does not support the hypothesis that known common breast cancer susceptibility loci strongly 
modify the associations between established risk factors and breast cancer.
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ring finger protein 146 (RNF146), solute carrier family 4 member 
7 (SLC4A7), neurogenic locus notch homolog protein 2 (NOTCH2), 
RAD51-like 1 (RAD51L1) genes, or in the vicinity of these genes, 
as well as in gene-poor regions on chromosomes 2q35, 8q24, 6q25, 
and 5p12 (1–10).
These SNPs are genetic markers and do not necessarily repre-
sent the functional variants responsible for the association with 
breast cancer risk. Relatively little is known about the possible 
interplay between established epidemiological and genetic risk 
factors for breast cancer risk (11–19). Previous reports suggest that 
specific SNPs in FGFR2 (rs3750817 and rs1219648) modify the 
association between hormone replacement therapy (HRT) and 
breast cancer risk (13,14), although a large epidemiological study 
that included women from the Million Women Study did not 
confirm these findings (18).
Large-scale prospective data are needed to test reliably for in-
teractions, defined here as departures from a multiplicative odds 
ratio model for the joint association of the SNPs and the estab-
lished risk factors. In this study, we estimated interactions between 
17 SNPs, previously reported to be associated with breast cancer 
risk and reaching genome-wide statistical significance in at least 
one previous study (FGFR2-rs2981582, FGFR2-rs3750817, TNRC9-
rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 
CASP8-rs1045485, LSP1-rs3817198, COL1A1-rs2075555, 
COX11-rs6504950, RNF146-rs2180341, 6q25-rs2046210, 
SLC4A7-rs4973768, NOTCH2-rs11249433, 5p12-rs4415084, 
5p12-rs10941679, RAD51L1-rs999737) (1–10), and nine established 
risk factors (age at menarche, parity, age at menopause, use of HRT, 
family history, height, body mass index (BMI), smoking status, and 
alcohol consumption), in the National Cancer Institute’s Breast and 
Prostate Cancer Cohort Consortium (BPC3), a large consortium of 
prospective cohort studies from Europe and the United States.
Subjects and Methods
Study Population
The BPC3 has been described in detail elsewhere (20). Briefly, the 
consortium includes large well-established cohorts assembled in 
the United States and Europe, which have both DNA samples and 
extensive questionnaire information. These cohorts are the 
American Cancer Society Cancer Prevention Study II (CPS-II) 
(21), the European Prospective Investigation into Cancer and 
Nutrition (EPIC) (22), the Nurses Health Study (NHS) (23), the 
Women’s Health Study (WHS) (24), the Prostate, Lung, 
Colorectal, Ovarian (PLCO) Cancer Screening Trial (25), and the 
Multiethnic Cohort (MEC) (26).
Case subjects were identified in each cohort by self-report with 
subsequent confirmation of the diagnosis from medical records or 
tumor registries and/or direct linkage with population-based 
tumor registries (method of breast cancer case confirmation varied 
by cohort). Control subjects were matched with case subjects by 
ethnicity and age and, in some cohorts, additional criteria, such as 
country of residence in EPIC. The requirement for each control 
subject was to be free of cancer up to the duration of follow-up of 
the matched case subject.
Most of the subjects were white and of European descent. One 
cohort (MEC) provided most of the DNA samples from nonwhite 
subjects. In total, we genotyped (described below) 8576 case sub-
jects and 11 892 control subjects, of whom 7023 case subjects and 
10 065 control subjects were white (of European descent), 389 case 
subjects and 423 control subjects were Latino, 430 case subjects 
and 471 control subjects were African American, 552 case subjects 
and 580 control subjects were Asian American (mostly of Japanese 
origin), and 148 case subjects and 297 control subjects were Native 
Hawaiian. Table 1 describes the study populations in detail.
Informed consent was obtained from all subjects, and the pro-
ject was approved by the relevant institutional review boards for 
each cohort.
SNP Selection and Genotyping
We selected SNPs that were reported to be associated with breast 
cancer risk and reached a commonly accepted threshold for 
genome-wide statistical significance (P < 5 × 1027) (27) in at least 
one previous study. For two loci, we genotyped either the SNP 
reported in the original study or a surrogate in a complete or 
nearly complete linkage disequilibrium, based on data from the 
International HapMap Project (28,29). Namely, we genotyped 
rs4415084 or surrogate rs920329 (correlation coefficient r2 = 0.981 
in HapMap Centre d’Etude du Polymorphisme Humain [CEPH] 
or CEU Utah residents with ancestry from Northern and 
Western Europe); likewise, we genotyped rs999737 or surrogate 
rs10483813 (r2 = 1 in HapMap CEU). We selected two SNPs from 
the locus on chromosome 5p12. Both were reported to be strongly 
CONTEXT AND CAVEATS
Prior knowledge
Genome-wide association studies have identified many single-
nucleotide polymorphisms (SNPs) that are associated with breast 
cancer risk. Several established epidemiological factors are also 
associated with breast cancer risk. However, it is not well under-
stood whether the interactions between the SNPs and established 
risk factors can modify breast cancer risk.
Study design
Prospective nested case–control study within the National Cancer 
Institute’s Breast and Prostate Cancer Cohort Consortium (BPC3) to 
analyze the associations of 17 germline SNPs with breast cancer 
risk. Interactions between these 17 SNPs and nine established risk 
factors (age at menarche, parity, age at menopause, use of 
hormone replacement therapy, family history, height, body mass 
index, smoking status, and alcohol consumption) were tested.
Contribution
Of the 17 SNPs, 14 showed association with breast cancer risk. 
After correction for multiple testing, no statistically significant inter-
actions between the 17 SNPs and the nine risk factors were detected.
Implication
The common polymorphisms associated with breast cancer risk 
tested in this study did not modify the association between estab-
lished risk factors and breast cancer risk.
Limitation
Majority of the white subjects were of European descent, so 
analyses in other race or ethnicity were of limited statistical power.
From the Editors
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associated with breast cancer risk (6), but there was only moderate 
linkage disequilibrium between the two SNPs (r2 = 0.5 in the 
Icelandic population of the original study; r2 = 0.51 in HapMap 
CEU subjects), and they could possibly represent two distinct sus-
ceptibility loci.
Genotyping assays were designed and performed using Taqman 
assays with reagents by Applied Biosystems (Foster City, CA). 
Details of primers and probes are available upon request. 
Genotyping of the breast cancer case subjects and control subjects 
was performed in four laboratories (located at the University of 
Southern California, the US National Cancer Institute, Harvard 
School of Public Health, and the German Cancer Research 
Center, DKFZ). Laboratory personnel were blinded to case– 
control status. Within each study, blinded duplicate samples 
(approximately 5%) were also included and concordance of these 
samples was greater than 99%.
The genotyping success rate was 94.14% overall (range 
93.09%–95.62%). It was 97.11% (range 95.28%–98.86%) for 
white subjects of European descent.
Data Filtering and Statistical Analysis
DNA samples were excluded from further analysis if more than 
25% of the SNPs in the samples failed genotyping. Genotype 
frequencies of each SNP were checked for deviation (P < 1023) 
from the expected Hardy–Weinberg proportions among control 
subjects of European ancestry within a cohort or overall.
We examined whether each of the 17 selected SNPs (1–10) was 
associated with risk of breast cancer by fitting for each SNP an 
unconditional logistic regression model involving the SNP and 
adjustment for age at baseline, study, ethnicity (within MEC), and 
country (for EPIC). An additional analysis was run with a model 
including also the established risk factors as adjustment variables. 
Genotypes were coded either as allele count (trend test) or as three 
categories: for major-allele homozygotes (reference category), for 
heterozygotes, and for minor-allele homozygotes (two df test). We 
calculated Ptrend for each SNP as P value when coding minor alleles 
as trend variable. We performed these analyses in all subjects, sepa-
rately for each ethnicity, and (for white subjects of European descent 
and African Americans) separately for each study within ethnicity.
We investigated the hypothesis that the odds ratios associated 
with nine established risk factors for breast cancer (age at men-
arche, parity, age at menopause, use of HRT, family history, 
height, BMI, smoking status, and alcohol consumption) could be 
modified by any one of 17 SNPs. Information on these established 
risk factors was recorded prospectively at the time the women 
joined the study or provided a blood sample (ie, before the diagno-
sis of breast cancer among the case subjects and at an equivalent 
time for the control subjects).
To test for interactions between SNPs and the established risk 
factors, we analyzed two models for each SNP—one with terms for 
the SNP and the covariate of interest, the other including addi-
tional interaction term(s) between the SNP and the covariate. 
SNPs were coded as counts of minor alleles (trend variable), and 
other risk factors were coded in categories. Both models were 
adjusted for age at baseline, study, ethnicity (within MEC), and 
country (for EPIC). We then computed the likelihood ratio test 
between the two models to test for a particular form of interaction, 
namely, departure from a multiplicative odds ratio model for the 
joint association of a genetic marker and an established risk factor. 
We did this for each SNP–covariate pair. The non-SNP variables 
were grouped as follows: age at menarche (early, ≤11 years; inter-
mediate, 12–13 years; late, ≥14 years); age at menopause (early, 
≤44 years; intermediate, 45–49 years; late, ≥50 years); BMI (BMI < 
25 kg/m2; 25 kg/m2 ≤ BMI < 30 kg/m2; BMI ≥ 30 kg/m2, separately 
for pre- and postmenopausal women); alcohol intake (non-drinker, 
<1 g alcohol per day; moderate drinker, <14 g alcohol per day; 
regular drinker, 14 g alcohol per day); height (<1.63 m or ≥1.63 m); 
use of HRT (never or ever use of any type of HRT, never or ever 
use of estrogen-only HRT, never or ever use of combined estrogen 
plus progestin HRT); smoking status (never, former, or current 
smoker); family history (presence or absence of first-degree rela-
tives diagnosed with breast cancer); and parity (nulliparous or 
parous). We also computed stratum-specific odds ratios and 95% 
confidence intervals (CIs) for each SNP. An additional analysis was 
performed with models including not only each covariate of in-
terest but also all other established risk factors. To correct for 
multiple testing of the 153 (17 × 9 = 153) tests performed, we eval-
uated statistical significance at an adjusted P value threshold (P = 
.05/153 = 3 × 1024).
We performed case-only analyses to test for differences in the 
associations of SNP with breast cancer risk with respect to dif-
ferent prognostic factors. Specifically, we compared estrogen 
receptor–negative (ER2) case subjects with ER-positive (ER1) case 
subjects as the reference, and in a similar fashion progesterone 
receptor–negative (PR2) case subjects with PR-positive (PR1) 
case subjects, advanced case subjects with nonadvanced case sub-
jects (advanced disease was defined as having regional or distant 
metastasis), and case subjects diagnosed before the age of 55 with 
case subjects diagnosed after the age of 55 years. A statistically 
significant association between an SNP and breast cancer sub-
group in this analysis was interpreted as a statistically significant 
heterogeneous association of the SNP on the different disease 
characteristics. We also performed case–control analyses by sub-
groups according to ER1 or ER2 status, PR1 or PR2 status, 
advanced or nonadvanced disease, and age at diagnosis.
For all subjects, analyses were performed after adjusting for 
cohort, age, country within EPIC, study phase in NHS, and eth-
nicity for MEC and PLCO.
We calculated the interaction odds ratios (ie, ORs of the inter-
action term between each SNP and each established risk factor) 
that we could detect in our study with 80% or greater power. The 
power calculation was performed assuming a multiplicative model 
of interaction and taking into account multiple testing. For these 
calculations, we considered only the SNPs that showed a statisti-
cally significant association with breast cancer risk.
Mathematical models for all analyses are reported in the 
Supplementary Methods (available online). All statistical tests were 
two-sided, and all statistical analyses were performed with SAS 
version 9.2 (SAS Institute Inc, Cary, NC).
Results
After exclusions, the analyses included 8576 breast cancer case 
subjects and 11 892 control subjects from the six cohorts. The 
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summary characteristics of the study population are shown in 
Table 1 and Supplementary Table 1 (available online). Case sub-
jects and control subjects were predominantly white and were of 
European descent (7023 case subjects and 10 065 control subjects; 
overall 83%) and peri- or postmenopausal (7097 case subjects and 
9448 control subjects; overall 81%) at the time of enrollment. The 
mean age at diagnosis was 62.39 (SD = 9.08 years). All established 
risk factors were associated with breast cancer risk, as shown in 
Supplementary Table 2 (available online). None of the SNPs were 
excluded from further analyses because of deviation from fitness 
for Hardy–Weinberg proportion (P < 1023).
For each SNP, the genotype frequencies in case subjects and 
control subjects and the association with breast cancer risk (Ptrend = 
2.57 × 1023–3.96 × 10219) are shown in Table 2. Associations 
between SNPs and breast cancer risk did not differ materially from 
those reported previously (1–10), except for three SNPs that 
did not show evidence of association with breast cancer risk 
(LSP1-rs3817198, Ptrend = .89; COL1A1-rs2075555, Ptrend = .42; 
and RNF146-rs2180341, Ptrend = .11). Similar results were obtained 
when we corrected for multiple testing and adjusted for the established 
breast cancer risk factors; all SNPs remained statistically significantly 
associated with breast cancer risk (Ptrend = .023–1.02 × 10211), except 
LSP1-rs3817198 (Ptrend = .33), COL1A1-rs2075555 (Ptrend = .74), and 
RNF146-rs2180341 (Ptrend = .60), as shown in Supplementary Table 
3 (available online). Tests of heterogeneity for the associations 
between SNPs and breast cancer risk of SNPs across cohorts and 
different ethnic groups (Supplementary Table 4, available online) 
were not statistically significant, with the exception of 
TNRC9-rs3803662 (Pheterogeneity = 9.18 × 1025) that showed statisti-
cally significant association with breast cancer risk in the white 
(P = 9.84 × 1026) and African American (P = .004) subjects, an 
association of borderline statistical significance among Hispanic 
subjects (P = .04), and a non-statistically significant association 
in Asian American (P = .53) and Native Hawaiian (P = .65) 
subjects.
Table 3 shows the results of interaction tests between each of 
the 17 SNPs and the established risk factors, and the P values of 
likelihood ratio tests comparing models with or without interac-
tion term(s) between SNPs and covariates are presented. The 
detailed results of tests for associations between SNPs and breast 
cancer risk within each stratum of established risk factors are 
shown in Supplementary Table 5 (available online). After correc-
tion for multiple testing, we observed no statistically significant 
interactions in any of the 153 (17 × 9 = 153) tests (adjusted P value 
threshold = .05/153 = 3 × 1024). The strongest statistical signifi-
cance was observed for interaction between 5p12-rs10941679 on 
chromosome 5 and use of estrogen-only HRT (P = .0072) (Table 3). 
This SNP was associated with increased breast cancer risk in users 
and nonusers of estrogen-only HRT but more strongly associated 
in the group of users, as measured by odds ratio of an increasing 
number of minor alleles (nonusers, ORallele = 1.10, 95% CI = 1.02 
to 1.19; users, ORallele = 1.35, 95% CI = 1.19 to 1.53; ORinteraction = 
1.22, 95% CI = 1.06 to 1.41). We did not observe any interaction 
between 5p12-rs10941679 and use of HRT overall (P = .97), or 
with combined estrogen plus progestin HRT (P = .80). Analyses 
taking into account the duration of HRT use showed that 
COX11-rs6504950 was associated more strongly with breast 
cancer risk in women who used HRT for more than 5 years than 
in women who used HRT for less than 5 years, although the inter-
action did not reach statistical significance when corrected for 
multiple testing (P = .0035) (data not shown). When we adjusted 
the statistical models for all established breast cancer risk factors, 
we did not observe any statistically significant interaction with 
the same adjusted P value threshold (Supplementary Table 6, 
available online). It was previously suggested that FGFR2-rs3750817 
shows an interaction with HRT (13); however, we did not find any 
clear evidence of interaction with the use of HRT. Indeed, 
point estimates of risks associated with this SNP in HRT users 
(OR = 0.87, 95% CI = 0.81 to 0.94) and nonusers (OR = 0.79, 95% 
CI = 0.73 to 0.85) differed only at borderline level of statistical 
significance (P = .05; Table 3 and Supplementary Tables 5 and 7, 
available online).
To investigate whether the SNPs were associated with partic-
ular forms of breast cancer, we analyzed the associations between 
17 SNPs and breast cancer risk by subgroups of advanced or non-
advanced disease, by ER or PR status, and by age at diagnosis 
(Table 4). We evaluated heterogeneity of associations between 
SNPs and breast cancer risk by case–case comparisons between 
case subjects grouped according to clinical variables. After 
correction for multiple testing for 17 SNPs (adjusted P value 
threshold = .05/17 = .0029), the results of the subgroup analyses 
showed that 5p12-rs10941679 was statistically significantly associ-
ated with greater risk of PR1 breast cancer than PR2 breast cancer 
(Pheterogeneity = .0028), and FGFR2-rs2981582 was statistically signifi-
cantly associated with greater risk of ER1 breast cancer than ER2 
breast cancer (Pheterogeneity = .0016). Additionally, if we considered 
associations showing P less than or equal to an arbitrary threshold 
of .01, another SNP on locus 5p12, rs4415084, also showed asso-
ciation with greater risk of PR1 breast cancer than PR2 breast 
cancer (Pheterogeneity = .010). TNRC9-rs3803662 and the second SNP 
in the FGFR2 gene, rs3750817, were associated with greater risk of 
ER1 breast cancer than ER2 breast cancer (Pheterogeneity = .0053 and 
.0063, respectively) (Table 4). FGFR2-rs2981582 was also associ-
ated with a higher risk of being diagnosed with breast cancer at 
younger age (Pheterogeneity = .0042), and similar was the observation 
for COL1A1-rs2075555 (Pheterogeneity = .0098) (Table 4). However, 
COL1A1-rs2075555 did not show an association with breast cancer 
risk overall in this study (Table 2). The SNP 8q24-rs13281615 was 
previously reported to be associated with risk of ER1 breast cancer, 
but not with risk of ER2 breast cancer (30). However, we did not 
observe any evidence of a differential association between this SNP 
and breast cancer risk depending on ER status (Pheterogeneity = .13) 
(Table 4). The results of the subgroup analyses are shown in details 
in Supplementary Table 8 (available online).
Discussion
In this article, we report findings from a consortium of large pro-
spective studies of possible interactions between 17 polymor-
phisms that have been associated with breast cancer and established 
risk factors for the disease. Data were examined using a nested 
case–control design within the National Cancer Institute’s BPC3 
and included 8576 case subjects with breast cancer and 11 892 
control subjects without breast cancer.
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We replicated all of the previously reported associations 
between SNPs and breast cancer risk, except for LSP1-rs3817198, 
COL1A1-rs2075555, and RNF146-rs2180341, which did not show 
association with breast cancer risk. It is worth noting that the asso-
ciation with RNF146-rs2180341 was reported only in a small study 
focusing on Ashkenazi Jews (7), which did not include replication 
in samples of other populations. Likewise, the association with 
COL1A1-rs2075555 was reported by a single study with only 58 
cases of breast cancer, nested in the Framingham Heart Study (4). 
In light of the lack of association between these two SNPs and 
breast cancer risk in our study, we think that they most likely rep-
resent false positives or are relevant only to specific populations, 
such as women of Ashkenazi Jewish ancestry. The association 
between LSP1-rs3817198 and breast cancer risk was investigated 
in several studies: A statistically significant association at genome-
wide level (albeit with a rather low ORallele = 1.07) was reported by 
Easton et al. (1) but not confirmed in subsequent GWAS (8,9). 
Our results suggest that the association between this polymor-
phism and breast cancer risk is at best weak (ORallele = 1.00; 95% 
CI = 0.95 to 1.04; Ptrend = .89). For some of the other SNPs, whose 
associations with breast cancer risk are clearly replicated in our 
study, we found slightly lower odds ratios than reported in pre-
vious publications (1–10). However, the direction of associations 
was consistently the same, and our confidence intervals largely 
overlapped with those of the previous reports.
Previous studies have reported possible interactions between 
breast cancer susceptibility loci and established risk factors 
(13–17). These studies focused mainly on FGFR2 and MAP3K1 
and hormonal and reproductive factors, particularly the use of 
HRT. A recent study within the Women’s Health Initiative (13) 
showed a possible interaction between SNPs in FGFR2 and HRT 
use. Another recent study (14) showed an interaction between 
SNP FGFR2-rs1219648 and use of combined HRT in women of 
European ancestry. These studies had smaller sample sizes than 
ours. FGFR2-rs1219648 is in strong linkage disequilibrium with 
FGFR2-rs2981582 (Pearson correlation coefficient r2 = 1) (28,29), 
which did not show any evidence of interaction with HRT overall 
or with subtypes of HRT in this study (Table 3 and Supplementary 
Table 5, available online). As shown in the article by Prentice et al. 
(13), the FGFR2 SNP showing the strongest interaction with HRT 
was rs3750817 (Pinteraction = .046 for use of estrogen-only HRT, and 
Pinteraction = .033 for use of estrogen–progestin HRT), which is only 
in modest linkage disequilibrium with rs2981582 (Pearson corre-
lation coefficient r2 = 0.47). We genotyped rs3750817 in all the 
case subjects and control subjects in our analyses but did not 
observe any clear evidence of interaction with use of HRT. There 
Table 4. Heterogeneity of associations between SNPs and breast cancer risk by different prognostic factors*
Stratification variable, P‡
SNP  Gene Chr Location, bp† Stage§ Age at diagnosisǁ ER¶ PR#
rs11249433 NOTCH2 1 120,982,136 .75 .83 .085 .79
rs1045485 CASP8 2 201,857,834 .23 .38 .96 .22
rs13387042 Intergenic 2 217,614,077 .73 .96 .12 .21
rs4973768 SLC4A7 3 27,391,017 .078 .47 .090 .13
rs4415084** Intergenic 5 44,698,272 .34 .14 .21 .010
rs10941679 Intergenic 5 44,742,255 .23 .11 .10 .0028
rs889312 MAP3K1 5 56,067,641 .29 .17 .067 .48
rs2180341 RNF146 6 127,642,323 .86 .98 .80 .39
rs2046210 Intergenic 6 151,990,059 .51 .94 .46 .50
rs13281615 Intergenic 8 128,424,801 .89 .65 .13 .094
rs2981582 FGFR2 10 123,342,308 .24 .0042 .0016 .013
rs3750817 FGFR2 10 123,322,567 .73 .80 .0063 .51
rs3817198 LSP1 11 1,865,583 .35 .40 .58 .85
rs999737†† RAD51L1 14 68,104,435 .059 .15 .85 .48
rs3803662 TNRC9 16 51,143,843 .38 .59 .0053 .014
rs2075555 COL1A1 17 45,629,290 .77 .0098 .98 .55
rs6504950 COX11 17 50,411,470 .69 .077 .98 .078
* We performed case-only analysis to test for differences of the SNP association with breast cancer risk with respect to different prognostic factors. Specifically, 
we compared advanced case subjects with nonadvanced case subjects (advanced disease was defined as having regional or distant metastasis), case subjects 
diagnosed before the age of 55 years with case subjects diagnosed after 55 years, ER-negative (ER2) case subjects with ER-positive (ER1) case subjects (ref-
erent) and in a similar fashion PR-negative (PR2) case subjects with PR-positive (PR1) case subjects (referent). Analyses were performed for all subjects adjust-
ing for cohort, age, country within the European Prospective Investigation into Cancer and Nutrition (EPIC), study phase in the Nurses’ Health Study (NHS), and 
ethnicity for the Multiethnic Cohort (MEC) and the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial. bp = base pair; Chr = chromosome; ER = 
estrogen receptor; PR = progesterone receptor; SNP = single-nucleotide polymorphism.
† P values were calculated using two-sided Mantel–Haenszel test for heterogeneity.
‡ National Center for Biotechnology Information genome build 36 (http://genome.ucsc.edu/cgi-bin/hgGateway).
§ Advanced vs nonadvanced breast cancer case subjects (advanced disease was defined as having regional or distant metastasis).
ǁ Case subjects diagnosed at age younger than 55 years vs diagnosed after 55 years of age.
¶ ER-positive breast cancer case subjects vs ER-negative breast cancer case subjects.
# PR-positive breast cancer case subjects vs PR-negative breast cancer case subjects.
** 5p12-rs4415084 or surrogate 5p12-rs920329 (Pearson correlation coefficient r2 = 0.981 in HapMap CEU).
†† RAD51L1-rs999737 or surrogate RAD51L1-rs10483813 (Pearson correlation coefficient r2 = 1 in HapMap CEU).
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was no evidence for interaction when we analyzed separately the 
use of estrogen-only HRT or combined estrogen plus progestin 
HRT.
A recent case–control study performed in a Japanese population 
(15) showed interactions between SNPs in FGFR2 and family his-
tory of breast cancer, age at menarche, and parity. We did not 
observe any statistically significant interactions between SNPs 
FGFR2-rs2981582 or FGFR2-rs3750817 and any of these risk 
factors. The study by Kawase et al. (15) had a much smaller sample 
than ours (456 case subjects and 912 control subjects), and statis-
tical significance of the interactions reported was modest (the 
strongest result was observed for interaction with family history of 
breast cancer Pinteraction= .003); therefore, these could be chance 
findings.
Our results on interactions between SNPs and established risk 
factors are similar to those obtained in studies of comparable 
sample size, performed in the Million Women Study (18) and the 
Breast Cancer Association Consortium (19). Namely, no statisti-
cally significant interactions between SNPs and established breast 
cancer risk factors were detected in those studies, when multiple 
testing was taken into account (18,19).
Our study had greater than 80% power to detect interaction 
odds ratios (ie, ORs of the interaction term between each SNP and 
each established risk factor) ranging between 1.20 and 1.47 
between the SNPs and the risk factors we considered. The power 
calculation was performed assuming a multiplicative model of in-
teraction and taking into account multiple testing. Thus, we had a 
reasonably good chance to detect moderately large interactions 
between SNPs and established risk factors. This is also shown by 
the fact that 95% confidence intervals around interaction odds 
ratios were rather narrow for most SNP-established risk factor 
pairs (Supplementary Table 7, available online).
We cannot exclude the existence of real interactions of smaller 
magnitude (including interactions between SNPs and established 
risk factors that did not show a statistically significant association 
with breast cancer risk or had a relatively small association with 
breast cancer risk), which our study was not sufficiently powered to 
detect. If such interactions exist, they may shed light on poorly 
understood biological mechanisms, including the hitherto 
unknown function of most SNPs studied here. However, the rele-
vance of such small interactions in terms of risk assessment and 
prevention would be limited.
Results from subgroup analyses on clinical characteristics of tumors 
were generally in agreement with previous reports (3,6,30–32), 
including a meta-analysis of all published data (32). Findings from 
previous studies suggested that several SNPs are predominantly 
associated with ER1 breast cancer: TNRC9-rs3803662 (3,30–32), 
5p12-rs4415084 (6), 5p12-rs10941679 (6), FGFR2-rs2981582 
(6,30–32), 8q24-rs13281615 (30). In addition, FGFR2-rs2981582 
was also reported to be more strongly associated with PR1 cancers 
than with PR2 cancers (30). The SNP 2q35-rs13387042 was 
reported to be associated exclusively with ER1 and PR1 cancers 
(3), although later reports have shown that it is associated with 
both receptor-positive and receptor-negative cancers (31,32). In 
our data, SNPs on chromosome 5p12, FGFR2 and TNRC9 were 
preferentially associated with ER1 and/or PR1 breast cancer. In 
addition, SNP 2q35-rs13387042 showed a strongly statistically 
significant association with risk in ER1 and PR1 cases but not with 
ER2 and PR2 cases, although the heterogeneity was not statisti-
cally significant in our data, in agreement with previous studies 
(31,32). Because ER and PR status are the major markers of breast 
cancer subtypes, these observations suggest that inherited risk 
variants of these subtypes may vary. Contrary to one previous 
report (30) but consistent with results from a second study (32), we 
did not observe any evidence that SNP 8q24-rs13281615 had a 
stronger association with breast cancer risk depending on ER or 
PR status.
Our study has a few limitations. The vast majority of white 
subjects in the study are of European descent, and statistical power 
for analyses in other ethnicities is limited. In addition, many statis-
tical tests were performed and, given that there were no a priori 
hypotheses about the possible interactions of SNPs and established 
risk factors, our findings should be taken with caution. Nevertheless, 
this is one of the largest cohort studies to systematically investigate 
possible interactions between major established risk factors for 
breast cancer and polymorphisms in the known susceptibility 
regions. It is very unlikely that we had nondifferential measure-
ment error to the extent that could be a serious flaw in our study. 
Genotyping quality was monitored by a series of intra- and inter-
laboratory measures, including blind duplicated samples and 
measures of deviation from Hardy–Weinberg equilibrium. With 
respect to the established risk factors we included in our analyses, 
it is known that they are reliably measured in prospective cohorts, 
as documented by specific validation studies performed in some of 
the BPC3 cohorts (33–37).
Our study provides evidence against the hypothesis that 
common polymorphisms associated with breast cancer risk strongly 
modify the association of established factors with breast cancer 
risk. Our null findings are important given the size, prospective 
design, and the comprehensive approach of our study. However, 
our results do not rule out small departures from a multiplicative 
odds model for the joint association of pairs of individual SNPs 
and risk factors, nor does absence of departure from a multiplica-
tive odds model necessarily imply that these genetic loci and risk 
factors do not interact in some causal mechanism. Moreover, 
absence of interaction as we have defined it here does not imply 
absence of a “public health interaction,” where the benefit from 
reducing a risk factor in terms of absolute risk reduction differs 
across genotypes (38).
In conclusion, we studied almost 9000 women with breast can-
cer and 12 000 control subjects without breast cancer and showed 
that the 17 low-penetrance breast cancer susceptibility polymor-
phisms studied here do not strongly interact with established risk 
factors.
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